%0 Journal Article
%T Varfarina e femprocumona: experi¨ºncia de um ambulat¨®rio de anticoagula£¿£¿o
%A Leiria
%A Tiago Luiz Luz
%A Pellanda
%A Lucia
%A Miglioranza
%A Marcelo Haertel
%A Sant'Anna
%A Roberto Tofani
%A Becker
%A Lucas S.
%A Magalh£¿es
%A Eros
%A Lima
%A Gustavo Glotz de
%J Arquivos Brasileiros de Cardiologia
%D 2010
%I Sociedade Brasileira de Cardiologia - SBC
%R 10.1590/S0066-782X2010000100008
%X background: oral anticoagulants are broadly used in cardiology. however, it is still necessary to evaluate their use in clinical practice. objectives: to describe the differences in the maintenance of anticoagulation control, as well as the incidence of hemorrhagic and thromboembolic events among users of warfarin and phenprocoumon. methods: non-concurrent cohort study of 127 patients using oral anticoagulation. results: phenprocoumon was the most frequently used anticoagulant in 60% of the patients. the prevalence of rni<2 at the last medical appointment was higher among warfarin users (46% vs. 19.5%; p<0.001). during the follow-up, phenprocoumon users were within the therapeutic range during 60.7% of the period, in comparison with 45.6% of warfarin users (or:1.84; 95%ci:1.59-2.13; p<0.001). the incidence of bleeding was 5.3/100 patients/year in the phenprocoumon group versus 18.8/100 patients/year in the warfarin group (rr: 3.5; 95%ci: 1.87-6.48; p<0.001). conclusion: patients that used warfarin remained at subtherapeutic levels for a longer period; however, they also presented more hemorrhagic events. phenprocoumon users were younger and had been using oral anticoagulation for longer periods, presenting fewer drug-related adverse events.
%K warfarin
%K phenprocumon
%K anticoagulants
%K hemorrhage
%K anticoagulants [administration]
%K anticoagulants [dosage].
%U http://www.scielo.br/scielo.php?script=sci_abstract&pid=S0066-782X2010000100008&lng=en&nrm=iso&tlng=en